Thyrocare Technologies Limited (THYROCARE.NS)
- Previous Close
659.80 - Open
660.90 - Bid --
- Ask --
- Day's Range
649.10 - 663.95 - 52 Week Range
439.00 - 722.65 - Volume
48,906 - Avg. Volume
115,475 - Market Cap (intraday)
34.684B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
53.64 - EPS (TTM)
12.21 - Earnings Date May 21, 2024 - May 25, 2024
- Forward Dividend & Yield 18.00 (2.85%)
- Ex-Dividend Date Apr 20, 2023
- 1y Target Est
784.00
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
www.thyrocare.com1,645
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: THYROCARE.NS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THYROCARE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THYROCARE.NS
Valuation Measures
Market Cap
34.94B
Enterprise Value
34.35B
Trailing P/E
53.99
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.38
Price/Book (mrq)
7.19
Enterprise Value/Revenue
6.21
Enterprise Value/EBITDA
24.75
Financial Highlights
Profitability and Income Statement
Profit Margin
11.82%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.54B
Net Income Avi to Common (ttm)
654.5M
Diluted EPS (ttm)
12.21
Balance Sheet and Cash Flow
Total Cash (mrq)
993.4M
Total Debt/Equity (mrq)
9.64%
Levered Free Cash Flow (ttm)
--
Research Analysis: THYROCARE.NS
Company Insights: THYROCARE.NS
THYROCARE.NS does not have Company Insights